ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout. (19th January 2015)

• Record Type: Journal Article
• Authors: Matsuo, Hirotaka; Tomiyama, Hiroyuki; Satake, Wataru; Chiba, Toshinori; Onoue, Hiroyuki; Kawamura, Yusuke; Nakayama, Akiyoshi; Shimizu, Seiko; Sakiyama, Masayuki; Funayama, Manabu; Nishioka, Kenya; Shimizu, Toru; Kaida, Kenichi; Kamakura, Keiko; Toda, Tatsushi; Hattori, Nobutaka; Shinomiya, Nariyoshi
• Is Part Of: Annals of clinical and translational neurology. Volume 2:Number 3(2015:Mar.)
• Page Start: 302
• Page End: 306
• Publication Date: 2015-01-19
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.167
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: Uric acid (urate) has been suggested to play a protective role in Parkinson's disease onset through its antioxidant activity. Dysfunction of ABCG2, a high‐capacity urate exporter, is a major cause for early‐onset gout based on hyperuricemia. In this study, the effects of a dysfunctional ABCG2 variant (Q141K, rs2231142) were analyzed on the ages at onset of gout patients ( N = 507) and Parkinson's disease patients ( N = 1015). The Q141K variant hastened the gout onset ( P = 0.0027), but significantly associated with later Parkinson's disease onset ( P = 0.025). Our findings will be helpful for development of more effective prevention of Parkinson's disease.